ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "randomized trials"

  • Abstract Number: 3134 • 2015 ACR/ARHP Annual Meeting

    Safety and Tolerability of Pirfenidone in Patients with Systemic Sclerosis Interstitial Lung Disease

    Dinesh Khanna1, Carlo Albera2, Aryeh Fischer3, James R. Seibold4, Nader A. Khalidi5, Ganesh Raghu6, Lorinda Chung7, Elena Schiopu1, Dan Chen8 and Eduard Gorina9, 1University of Michigan, Ann Arbor, MI, 2University of Turin, Turin, Italy, 3National Jewish Health and University of Colorado, Denver, CO, 4Scleroderma Research Consultants LLC, Litchfield, CT, 5McMaster University, Hamilton, ON, Canada, 6University of Washington, Seattle, WA, 7Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, 8Jazz Pharmaceuticals (formerly of InterMune), Palo Alto, CA, 9Formerly of InterMune, Brisbane, CA

    Background/Purpose: Interstitial lung disease (ILD) is a common and serious complication of systemic sclerosis (SSc). Pirfenidone, a novel antifibrotic agent, has been shown to be…
  • Abstract Number: 2525 • 2014 ACR/ARHP Annual Meeting

    Infliximab Versus Conventional Combination Treatment and Work Loss in Early RA over 7 Years: A Randomized Trial

    Jonas K Eriksson1, Heather Miller2, Johan A Karlsson3, Ingemar F Petersson4, Sofia Ernestam5, Pierre Geborek3, Ronald F van Vollenhoven2 and Martin Neovius1, 1Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, 2ClinTRID, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, 3Section of Rheumatology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden, 4Section of Orthopedics, Department of Clinical Sciences Lund, Lund University, Lund, Sweden, 5Department of Learning, Informatics and Medical Education (LIME), Karolinska Institutet, Stockholm, Sweden

    Background/Purpose: The introduction of TNF inhibitors has improved the treatment of RA, but at a substantial cost. The randomized Swefot trial compared the addition of…
  • Abstract Number: 2337 • 2014 ACR/ARHP Annual Meeting

    The Cost and Effectiveness of Various Recruitment Strategies in a Mind Body Clinical Trial Among Older Adults with Knee Osteoarthritis

    Jade V. Goldsmith1, Lori Lyn Price2, Jeffrey B. Driban3, William F. Harvey3 and Chenchen Wang3, 1Center for Integrative Medicine and Division of Rheumatology, Tufts Medical Center, Boston, MA, 2Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, 3Rheumatology, Tufts Medical Center, Boston, MA

    Background/Purpose : Recruitment and adherence are important and challenging factors that can determine the success of a clinical trial. Mind body therapies are an emerging and…
  • Abstract Number: 2139 • 2014 ACR/ARHP Annual Meeting

    Predictors of Radiologic Disease Progression during the Rheumatoid Arthritis Comparison of Active Therapies Trial

    Alan Erickson1, Denis Rybin2, Mary Brophy3, Robert Lew3, Ted R. Mikuls1, Timothy Moore4, Keri Hannagan2, Edward Keystone5 and James O' Dell1, 1Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, 2MAVERIC, VA Boston Heathcare System, Boston, MA, 3VA Boston Heathcare System, Boston, MA, 4Radiology, University of Nebraska Medical Center, Omaha, NE, 5University of Toronto and Mount Sinai Hospital, Toronto, ON, Canada

    Background/Purpose Halting joint damage is a central goal in the treatment of rheumatoid arthritis.  Much research has been conducted to identify factors associated with progressive…
  • Abstract Number: 2880 • 2013 ACR/ARHP Annual Meeting

    Impact Of Different End Points On The Patient Cohort Size Needed To Demonstrate The Efficacy Of a Therapeutic Intervention In Pss. A Post Hoc Analysis Of The Tears Study (Tolerance and efficacy of Rituximab in primary Sjogren Syndrome study)

    Valerie devauchelle-Pensec1, Sandrine jousse-Joulin2, Xavier Mariette3, Jean-Marie Berthelot4, Aleth Perdriger5, Eric Hachulla6, Xavier Puechal7, Véronique le Guern8, Jean Sibilia9, Jacques-Eric Gottenberg10, Laurent Chiche Sr.11, Vincent Goeb12, Gilles Hayem13, Jacques Morel14, Charles Zarnitsky15, Jean Jacques Dubost16, Jacques-Olivier Pers17, Divi Cornec18, Raphaèle Seror19, Emmanuel Nowak20 and Alain Saraux21, 1Department of rheumatology and unit of immunology (EA2216), Brest Occidentale university, Brest, France, 2Rheumatology/Immunology, CHU de la Cavale Blanche, Brest, France, 3Rheumatology Service, Bicêtre University Hospital, Le Kremlin Bicetre, France, 4Rheumatology Unit, Nantes University Hospital, Nantes, France, 5Rheumatology, Hôpital Sud, Rennes, France, 6Internal Medicine, Lille CEDEX, France, 7Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, 8Department of Internal Medicine, Hôpital Cochin, Paris, France, 9Division of Rheumatology, University Hospital of Strasbourg, Strasbourg, France, 10Strasbourg University Hospital, Strasbourg, France, 11Internal Medicine, CHU Marseille, Marseille, France, 12Rheumatology, Amiens University Hospital, Amiens, France, 13Rheumatology Unit, Bichat Hospital, Paris, France, 14Dpartment of Rheumatology, Lapeyronie Hospital, Montpellier, France, 15Rheumatology, Le Havre General Hospital, Le Havre, France, 16Rheumatology, CHU G.-Montpied, Clermont-Ferrand, France, 17Unit of immunology, EA 2216, Brest Occidentale University, Brest, France, 18Department of rheumatology, Brest Occidentale University, Brest, France, 19Rheumatology, Bicetre university hospital, LE Kremlin-Bicetre, France, 20CIC, CHU Brest, Brest, France, 21Department of rheumatology and unit of immunology (EA 2216), Université Brest Occidentale, Brest, France

    Background/Purpose: To calculate the sample sizes needed in future randomized controlled trials (RCTs) testing a therapeutic intervention in pSS, methodologists usually rely on data obtained…
  • Abstract Number: 2691 • 2013 ACR/ARHP Annual Meeting

    Results Of The Strass Trial Regarding Impact Of Progressive Spacing Of Tnf-Blocker Injections In Rheumatoid Arthritis Patients In Das28 Remission: Is There a Difference Between Drugs – Adalimumab and Etanercept – Or Their Mode Of Use – Monotherapy Or Combination?

    Bruno Fautrel1, Thao Pham2, Jacques Morel3, Toni Alfaiate4, Emmanuelle Dernis5, Philippe Gaudin6, Olivier Brocq7, Elisabeth Solau-Gervais8, Jean-Marie Berthelot9, Jean-Charles Balblanc10, Xavier Mariette11 and Florence Tubach12, 1Paris 6 – Pierre et Marie Curie University; AP-HP, Rheumatology, Pitié-Salpêtrière Hospital, - GRC-UPMC 08 – EEMOIS, Paris, France, 2Rheumatology Department, Sainte Marguerite Hospital, Marseille, France, 3Department of Rheumatology, Hôpital Lapeyronie, Montpellier, France, 4Biostatistics, Bichat Hospital, AP-HP, Paris, France, 5Le Mans Hospital, Le Mans, France, 6Rheumatology Department, CHU Hôpital Sud, Grenoble Teaching Hospital, Echirolles, France, 7Hospital of Princesse Grâce de Monaco, Monaco, France, 8Rheumatology, University Hospital of Poitiers, Poitiers, France, 9Rheumatology Unit, Nantes University Hospital, Nantes, France, 10Rheumatology, Centre Hospitalier Général de Belfort, Belfort, France, 11Rheumatology Service, Bicêtre University Hospital, Le Kremlin Bicetre, France, 12INSERM, Universite Paris Diderot, Paris, France

    Background/Purpose: The STRASS trial was an 18-month randomized controlled trial, conducted in established RA patients in DAS28 remission with etanercept (ETA) or adalimumab (ADA), comparing…
  • Abstract Number: 2329 • 2013 ACR/ARHP Annual Meeting

    Improvements In Physical Function Correlate With Improvements In Health Related Quality Of Life: Reported Outcomes In Rheumatoid Arthritis Patients Treated With Tofacitinib: Results From 3 Randomized Phase 3 Trials

    V. Strand1, R. E. Alten2, C. I. Nduaka3, R. Riese3, D. Gruben3, S. H. Zwillich3, J. Andrews3 and G. Wallenstein3, 1Adjunct, Division of Immunology / Rheumatology, Stanford University, Palo Alto, CA, 2Department of Internal Medicine II, Schlosspark-Klinik, University Medicine, Berlin, Germany, 3Pfizer Inc, Groton, CT

    Background/Purpose: Tofacitinib is a novel, oral Janus kinase (JAK) inhibitor for the treatment of rheumatoid arthritis (RA). RA affects all domains of health-related quality of…
  • Abstract Number: 1977 • 2013 ACR/ARHP Annual Meeting

    Remission At 3 Or 6 Months and Radiographic Non-Progression At 12 Months In Methotrexate-Naïve Rheumatoid Arthritis Patients Treated With Tofacitinib Or Methotrexate: A Post-Hoc Analysis Of The ORAL Start Trial

    V. Strand1, D. van der Heijde2, R. Landewe3, E. B. Lee4, B. Wilkinson5, S. H. Zwillich5, J. Bradley5, C. Mebus5, B. Benda6 and D. Gruben5, 1Adjunct, Division of Immunology / Rheumatology, Stanford University, Palo Alto, CA, 2Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 3Division of Clinical Immunology and Rheumatology, Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands, 4Seoul National University, Seoul, South Korea, 5Pfizer Inc, Groton, CT, 6Pfizer Inc, Collegeville, PA

    Background/Purpose: Tofacitinib is a novel, oral Janus kinase (JAK) inhibitor for the treatment of RA. The importance of “treat to target” in RA to attain…
  • Abstract Number: 1471 • 2013 ACR/ARHP Annual Meeting

    Tofacitinib For Rheumatoid Arthritis: A Systematic Review and Meta-Analysis

    Maria A. Lopez-Olivo1, Maria E. Suarez-Almazor2 and Mahesh Bavineni3, 1General Internal Medicine, University of Texas. M.D Anderson Cancer Center, Houston, TX, 2The Department of General Internal Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX, 3Internal Medicine, Louisiana State University Lafayette, Lafayette, LA

    Background/Purpose: Tofacitinib was developed as a small molecule inhibitor of the Janus kinase (JAK) pathways that are central to the maintenance of the inflammatory state…
  • Abstract Number: 1418 • 2013 ACR/ARHP Annual Meeting

    Effects Of Smoking Status On Response To Treatment With Tofacitinib In Patients With Rheumatoid Arthritis

    J. M. Kremer1, J. D. Greenberg2, C. Turesson3, D. Gruben4, C. A. Mebus4, E. Bananis5 and T. Robinson6, 1Albany Medical College and The Center for Rheumatology, Albany, NY, 2Rheumatology, NYU Hospital for Joint Diseases, New York, NY, 3Lund University, Malmö, Sweden, 4Pfizer Inc, Groton, CT, 5Specialty Care, Pfizer Inc, Collegeville, PA, 6Pfizer Inc, Collegeville, PA

    Background/Purpose: Cigarette smoking is a known risk factor for developing rheumatoid arthritis (RA).1 Several recent observational studies suggest that cigarette smoking may be associated with…
  • Abstract Number: 1419 • 2013 ACR/ARHP Annual Meeting

    Mode Of Action Change Not Necessary After Failing The First Tumornecrosisfactor Inhibitor: Preliminary Results Of a Randomized Controlled Trial

    Sofie H.M. Manders1, Wietske Kievit2, Herman L.M. Brus3, Hein J. Bernelot Moens4, Andre Hartkamp5, Reinhard Bos6, Elisabeth Brouwer7, Henk Visser8, Harald E. Vonkeman9, Rene Westhovens10, Mart A.F.J. van de Laar11 and Piet LCM Van Riel1, 1Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, 2Department of Rheumatology and DREAM registry, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, 3TweeSteden Ziekenhuis, Tilburg, Netherlands, 4Ziekenhuisgroep Twente, Almelo, Netherlands, 5Reumatology, Jeroen Bosch Hospital, 's-Hertogenbosch, Netherlands, 6Rheumatology, Medical Center Leeuwarden, Leeuwarden, Netherlands, 7Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, 8Rheumatology, Rijnstate, Arnhem, Netherlands, 9Medisch Spectrum Twente & University of Twente, Enschede, Netherlands, 10Rheumatology, University Hospital KU Leuven, Leuven, Belgium, 11Rheumatology, Medisch Spectrum Twente & University of Twente, Enschede, Netherlands

    Background/Purpose: The best treatment option after a patient has failed a first TNFi is still unknown. Therefore the objective of this randomized open label study…
  • Abstract Number: 441 • 2013 ACR/ARHP Annual Meeting

    Tofacitinib, An Oral Janus Kinase Inhibitor: Safety Comparison In Patients With Rheumatoid Arthritis and An Inadequate Response To Nonbiologic Or Biologic Disease‑Modifying Anti-Rheumatic Drugs

    G. R. Burmester1, C Charles-Schoeman2, J. D. Isaacs3, T. Hendrikx4, K. Kwok5, S. H. Zwillich6 and R. Riese6, 1Department of Medicine/Rheumatology and Clinical Immunology and German Rheumatism Research Centre Berlin (DRFZ), Charité University Medicine Berlin, Berlin, Germany, 2University of California, Los Angeles, CA, 3Newcastle University, Newcastle-upon-Tyne, United Kingdom, 4Pfizer BV, Capelle aan den IJssel, Netherlands, 5Pfizer Inc, New York, NY, 6Pfizer Inc, Groton, CT

    Background/Purpose: Tofacitinib is a novel, oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). This analysis provides comparative safety data on the incidence…
  • Abstract Number: 443 • 2013 ACR/ARHP Annual Meeting

    Efficacy and Safety Analyses Of Tofacitinib From Pooled Phase 2, Phase 3 and Long-Term Extension Rheumatoid Arthritis Studies: US Compared With Non-US Populations

    S. B. Cohen1, Roy Fleischmann1, J. M. Kremer2, A. Koenig3, K. Kwok4, L. Wang5, C. a. Mebus5, R. Riese5 and T. Robinson3, 1Metroplex Clinical Research Center, Dallas, TX, 2Albany Medical College and The Center for Rheumatology, Albany, NY, 3Pfizer Inc, Collegeville, PA, 4Pfizer Inc, New York, NY, 5Pfizer Inc, Groton, CT

    Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor approved in the US for the treatment of rheumatoid arthritis at 5 mg BID. Phase (P) 3…
  • Abstract Number: 438 • 2013 ACR/ARHP Annual Meeting

    Tofacitinib, An Oral Janus Kinase Inhibitor, In A Rheumatoid Arthritis Open-Label Extension Study Following Adalimumab Therapy In A Phase 3 Randomised Clinical Trial

    M. C. Genovese1, R. F. van Vollenhoven2, B. Wilkinson3, L. Wang3, S. H. Zwillich3, D. Gruben3, B. Benda4 and T. V. Jones4, 1Division of Rheumatology, Stanford University, Palo Alto, CA, 2Clinical Trials Unit Department of Rheumatology, The Karolinska Institute, Stockholm, Sweden, 3Pfizer Inc, Groton, CT, 4Pfizer Inc, Collegeville, PA

    Background/Purpose: Tofacitinib is a novel, oral Janus kinase inhibitor for the treatment of rheumatoid arthritis. Here, we describe the efficacy and safety for adalimumab (ADA)…
  • Abstract Number: L9 • 2013 ACR/ARHP Annual Meeting

    Tofacitinib Monotherapy Versus Methotrexate in Methotrexate-Naïve Patients with Rheumatoid Arthritis: Radiographic, Clinical and Functional Comparison

    Roy Fleischmann1, E. B. Lee2, S Hall3, B. E. Wilkinson4, John D. Bradley5, D. Gruben4, T. Koncz6, S. Krishnaswami7, G. Wallenstein6, S. H. Zwillich4 and R.F. van Vollenhoven8, 1Metroplex Clinical Research Center, Dallas, TX, 2Seoul National University, Seoul, South Korea, 3Cabrini Health and Monash University, Melbourne, Australia, 4Pfizer Inc, Groton, CT, 5Pfizer Inc., Groton, CT, 6Pfizer Inc, New York, NY, 7Clinical Pharmacology, Pfizer Inc, Groton, CT, 8The Karolinska Institute, Stockholm, Sweden

    Background/Purpose: Tofacitinib is a novel, oral Janus kinase inhibitor for the treatment of RA. This Phase 3, 24-mo study (ORAL Start; NCT01039688) compared efficacy, including inhibition…
  • « Previous Page
  • 1
  • 2
  • 3
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology